Success Stories: Egyptian Graduate Researcher Wins NIW Approval for Innovative Research on Diabetes Therapies
Client’s Testimonial:
“Thank you so much for helping me to get approval for my EB2/NIW. I am willing to continue my journey till getting the green card with such a wonderful and professional attorney.”
On September 18th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Researcher in the field of Biomedical Sciences (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: Graduate Researcher
Country of Origin: Egypt
Country of Residence at the Time of Filing: United Arab Emirates
Approval Notice Date: September 18th, 2025
Processing Time: 1 year, 8 months, 2 days
Case Summary:
We are pleased to announce the EB-2 NIW (National Interest Waiver) approval of a graduate researcher from Egypt. At the time of filing, she was conducting research abroad, focusing on therapeutic targets for diabetes and cardiometabolic diseases. Her strong publication record, citation impact, and service as a peer reviewer established her as a compelling candidate for NIW approval.
Driving National Impact in Healthcare
The client is best known for her studies on oxidative stress, inflammation, and mitochondrial dysfunction. Her research shows how cannabinoids, terpenes, and natural compounds can reduce organ injury and improve treatment outcomes, including in cases of chemotherapy-induced damage. These contributions are particularly significant given that diabetes and its complications remain among the most widespread and costly health challenges in the United States.
By advancing strategies that could ease the burden of chronic disease and reduce long-term healthcare costs, her work supports U.S. priorities in public health and biomedical innovation.
Scholarly Credentials and Recognition
The client holds a Ph.D. in biomedical science and has authored 9 peer-reviewed journal articles, 6 of them as first author, as well as 2 abstracts, a first-authored book chapter, and a first-authored book. Her studies, published in respected journals such as Biomedicine & Pharmacotherapy, Frontiers in Pharmacology, and Nutrients, have been cited 192 times by independent researchers. Notably, six of her articles rank among the top 10 percent of most cited papers in clinical medicine for their publication years.
In addition, she has completed at least 2 reviews for journals, including Complementary Medicine and Pharmacology and the International Journal of Molecular Sciences. These contributions reflect her recognition as a trusted evaluator of research and her standing in the biomedical sciences community.
Expert Endorsements
Letters from independent experts confirmed her reputation for originality and impact. One recommender wrote:
“Through the results of [client]’s studies in biomedical sciences, countless individuals affected by diabetes are given better treatment methods, minimizing the fatalities caused by diabetes and diabetic cardiomyopathy.”
Such testimonials reinforced her profile as a researcher whose findings are not only scientifically innovative but also vital to public health.
NIW Approval and Outlook
The I-140 NIW petition was filed on January 16, 2024, and approved on September 18, 2025. USCIS recognized her scholarly output, citation influence, service as a reviewer, and the national importance of her proposed endeavor as sufficient to satisfy the NIW requirements.
With NAILG’s support, the client secured NIW approval and is now prepared to continue her research in the United States. Her ongoing studies are expected to contribute to the development of new therapies for diabetes and related conditions, strengthening U.S. leadership in biomedical science and chronic disease treatment.